796 F. Supp. 2d 277
D. Mass.2011Background
- Putative federal securities class action under the Exchange Act against Novelos Therapeutics, Inc. and CEO Palmin for purchases during Dec 14, 2009–Feb 24, 2010.
- Novelos pursued FDA approval for NOV-002 (oxidized glutathione) to treat advanced NSCLC; VAM originally developed Glutoxim andNOV-002; Phase ½ results were positive.
- Phase 3 trial began Nov 2006, enrolled 840 patients, compared NOV-002 + chemotherapy vs chemotherapy alone, with a 12.5 month median survival target and no interim analysis.
- Dec 2009–Feb 2010: statements by Palmin and BioMedReports suggested patients in trial were living longer; later reporting indicated control arm dynamics affected interpretation.
- Feb 24, 2010: Novelos disclosed primary endpoint not met; stock fell ~80% the next day, aligning with investor impact.
- Post-class-period discovery showed Phase 3 NOV-002 differed materially from Glutoxim/NOV-002 used in prior studies; VAM litigation followed.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Palmin's statements about survival were material misrepresentations | Urman asserted statements implied NOV-002 efficacy (longer survival) misleadingly. | Palmin's statements were not false on their face and reflected assumptions about control-group outcomes. | Not actionable misrepresentation; context and assumptions rendered not misleading. |
| Whether plaintiffs pled scienter adequately | Defendants knew or recklessly disregarded manufacturing changes affecting drug structure. | No cogent, compelling inference of scienter; IND amendments supported non-fraudulent understanding. | Insufficient strong inference of scienter; dismissal warranted. |
| Whether Section 20(a) control-person liability lies with Palmin | Palmin controlled underlying violations by virtue of role/family ties. | No underlying violation proven; control liability cannot stand alone. | Dismissed for lack of underlying 10(b) violation. |
| Whether dismissal should be with or without prejudice | Court dismisses without prejudice to allow amendment. |
Key Cases Cited
- Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007) (requires strong inference of scienter; totality of circumstances)
- Dura Pharm., Inc. v. Broudo, 544 U.S. 336 (2005) (economic loss and causation standards for 10b-5)
- Matrixx Initiatives, Inc. v. Siracusano, 131 S. Ct. 1309 (2011) (six-element pleading framework for 10b-5 claims)
- ACA Fin. Guar. Corp. v. Advest, Inc., 512 F.3d 46 (1st Cir. 2008) ( PSLRA pleading standards; strong inference standard)
- In re Par Pharm., Inc. Sec. Litig., 733 F. Supp. 668 (S.D.N.Y. 1990) (pleading specificity and falsity under PSLRA-like standards)
- Lirette v. Shiva Corp., 27 F. Supp. 2d 268 (D. Mass. 1998) (need for specific internal information to prove scienter)
- In re Boston Tech., Inc. Sec. Litig., 8 F. Supp. 2d 43 (D. Mass. 1998) (requirement of detailed knowledge to satisfy scienter)